Study of the early steps of the Hepatitis B Virus life cycle by Lu, Xuanyong & Block, Timothy
Int. J. Med. Sci. 2004 1(1): 21-33  21 
International Journal of Medical Sciences 
ISSN 1449-1907 www.medsci.org 2004 1(1):21-33 
©2004 Ivyspring International Publisher. All rights reserved 
Study of the early steps of the Hepatitis B Virus life cycle  Research paper 
 
Received: 2004.2.02 
Accepted: 2004.3.03 
Published:2004.3.10 
 
Xuanyong Lu, Timothy Block 
Jefferson Center for Biomedical Research and Agricultural Medicine, Department of 
Biochemistry and Molecular Pharmacology, Thomas Jefferson University, Philadelphia, 
USA 
A Ab bs st tr ra ac ct t    Hepatitis B virus (HBV) is a human pathogen, causing the serious liver disease. 
Despite considerable advances in the understanding of the natural history of 
HBV disease, most of the early steps in the virus life cycle remain unclear.  Virus 
attachment to permissive cells, fusion and penetration through cell membranes 
and subsequent genome release, are largely a mystery.  Current knowledge on 
the early steps of HBV life cycle has mostly come from molecular cloning, 
expression of individual genes and studies of the infection of duck hepatitis B 
virus (DHBV) with duck primary duck hepatocytes. However, considering of the 
difference of the surface protein of HBV and DHBV both in the composition and 
sequence, the degree to which information from DHBV applies to human HBV 
attachment and entry may be limited. A major obstacle to the study HBV 
infection is the lack of a reliable and sensitive in vitro infection system. We have 
found that the digestion of HBV and woodchuck hepatitis virus (WHBV) by 
protease V8 led to the infection of HepG2 cell, a cell line generally is refractory 
for their infection [Lu et al. J Virol. 1996. 70. 2277-2285. Lu et al. Virus 
Research. 2001. 73(1): 27-4]. Further studies showed that a serine protease 
inhibitor Kazal (SPIK) was over expressed in the HepG2 cells. Therefore, it is 
possible that to silence the over expressed SPIK and thus to reinstate the activity 
of indispensable cellular proteases can result in the restoration of the 
susceptibility of HepG2 cells for HBV infection. The establishing a stable cell line 
for study of the early steps of HBV life cycle by silencing of SPIK is discussed.  
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1.  Introduction 
The Hepatitis B virus (HBV), which belongs to the hepadnavirus family, is a small circular DNA 
virus containing a nucleocapsid and an envelope. HBV nucleocapsid contains a relatively small and 
incompletely double stranded 3.2 Kb DNA genome, viral polymerase and core protein. Its envelope is 
composed of viral surface proteins enclosed by a lipid membrane from host cells [1, 2]. In the serum of 
infected patients, there are both mature virion with viral DNA and subviral particles without viral DNA 
[3, 4].  Sub viral particles are overwhelmingly in excess to infectious particles, which is the majority of 
the two types [3, 4] 
The life cycle of HBV is believed to begin when the virus attaches to the host cell membrane via 
its envelope proteins. Then, the viral membrane fuses with the cell membrane and the viral genome is 
released into the cells [5, 6] After the viral genome reaches the nucleus, the viral polymerase converts 
the partial double stranded DNA (dsDNA) genome into covalently closed circle DNA (cccDNA). The 
cccDNA is believed to be the template for further propagation of pre-genomic RNA, which directs the 
synthesis of viral DNA and mRNA that encode all the viral proteins [2, 7, 8] HBV core particles are 
assembled in the cytosol following the encapsidation of pre-genomic RNA, which is then degraded 
during the reverse transcription of pre-genomic RNA into a complementary strand of DNA [9]. HBV 
surface proteins are initially synthesized and polymerized in the rough endoplasmic reticulum (RER). 
These proteins are transported to the post ER and pre-Golgi compartments where budding of the 
nucleocapsid follows [10]. The assembled HBV virion and sub-viral particles are transported to the 
Golgi for further modification of its glycans in the surface proteins, and then are secreted out of the host 
cell to finish the life cycle. HBV replication and viral protein synthesis in the infected cells are fairly 
well elucidated. However, the early steps of HBV infection including of the penetration of virus and 
release of its genome into host cells is uncertain. 
In general, the early step of virus infection in which the virus enters the cell can be divided into 
three stages:  attachment, fusion, and entry. Enveloped viruses usually entry by an attachment to the 
host cells, which usually is via the interaction of viral surface protein with the specific receptor on the 
cell membrane [11]. However, the attachment itself does not necessarily result in viral entry. The fusion 
of a viral envelope and cell membrane and the following viral genome release finally trigger the viral 
infection [12, 13]. The viral fusion occurs by one of at least two known mechanisms. The first requires 
a fusion of the viral envelope with the plasma membrane, leading to the release of the viral 
nucleocapsid.   HIV is an example of a virus that uses this type of mechanism to enter [12]. In the 
second mechanism, an endosomal compartment first takes up the attached virus. Later, the viral genome 
is released from this endosomal compartment into the cytoplasm by a process that may or may not 
depend upon a lowering of the pH to activate a virus-mediated fusogenic activity. In some virus/cell 
systems, such as those involving influenza virus [14] or paramyxoviruses [11, 13] exogenously adding 
protease generates infective virions from otherwise non-infective ones. The reason is that the 
proteolysis exposes the viral fusion sequence. The un-coating and the genome release occur instantly 
after virus fusion. The following transport of the viral genome to nucleus and the start of the virus 
replication finally complete the early steps of virus life cycle. 
2.  The attachment of HBV 
A major limitation to study HBV early steps of life cycle is lack of an in vitro infection system. 
Although HBV is considered highly efficient in establishing infection in people following parenteral 
exposure, tissue culture cells are curiously refractory for HBV infection [5, 15, 16, 17]. Although there 
is a growing body of data, recently most of the published information about the early stages of 
hepadnavirus infection is derived from duck hepatitis B virus (DHBV), since robust DHBV infectable 
tissue culture systems do exist. There are, however, significant differences between the duck and human 
hepatitis viruses.  For example, and perhaps of greatest relevance, human HBV envelope polypeptides, 
the likely mediators of entry, are N-glycosylated, whereas DHBV envelope polyepotides are not.  Thus, 
the degree to which information from DHBV applies to human HBV attachment and entry may be 
limited. 
The HBV surface protein antigens (HBsAg) are comprised of three carboxyl-co-terminal HBs 
proteins termed large (LHBs), middle (MHBs) and small (SHBs, also called major) protein [3, 4]. LHBs 
and MHBs also share the highly hydrophobic, repetitive, membrane-spanning S domain. In addition, Int. J. Med. Sci. 2004 1(1): 21-33  23 
MHBs has a 55 amino acid region called preS2, LHBs has an additional 109-120 amino acid long 
region called preS1 (dependent on the viral subtype) in their N-terminus (figure 1 A) [4]. Although 
HBV surface proteins must certainly mediate early steps in the virus life cycle, the precise role for each 
glycoprotein in the entry and egress of the virus is controversial.  We will thus discuss this now. 
LHBs is essential for attachment has been generally accepted. The studies of hepadnavirus in cell 
culture, especially with explanted human or duck primary liver cells, strongly suggest that LHBs is 
directly involved in the viral attachment [18, 19, 20]. The putative attachment site of HBV located in 
the preS1 was first reported by Neurath and his colleagues using anti-preS1 antibody [21, 22].  They 
found that the antibody against peptide corresponding to the HBV preS1 domain was virus-neutralizing 
and protective [21]. In 1989, Pontisso and his colleagues, using the membranes of surgically obtained 
human liver as a target, further confirmed the role of LHBs in the HBV attachment [23].  Recently, the 
attachment site of LHBs was functionally narrowed down to the amino acids 21–47 of preS1 by 
employing synthetic peptides. The results suggest that this binding site was not only required but also 
sufficient to attach specifically HepG2 cells (Figure 1 B) [24, 25]. Moreover, the antibody with this site 
has neutralized the HBV infection in Chimpanzee [19, 21]. It is interesting that, by mutagenesis studies 
and single cell attachment analysis, Paran and his colleagues found that the QLDPAF sequence within 
this preS1 region was crucial for cell attachment [25]. Further evidence to support this hypothesis is that 
this sequence is also found in the other virus and bacterial functioning as an adhesion or attachment 
determinant [25]. This suggests that the QLDPAF sequence may have a more general role in viral 
infection.  
There are differing reports about the role of MHBs in the generation of HBV in the transfected 
cells and in mediating HBV infection [8, 26]. MHBs seem to be absent in certain HBV variants from 
chronically infected patients [27, 28], suggesting a non essential function in the viral infection. On the 
other hand, misfolded MHBs seems to be able to interfere with the assembly of HBV virions in the 
persistently producing virus cell line HepG2.215 [29, 30]. Anti-preS2 antibody (that recognizes MHBs) 
can block HBV infection of primary human liver cell in vitro [31, 32] and chimpanzee liver cells in vivo 
[33] suggesting that MHBs are probably also involved in viral entry. HBV preS2 can specifically bind 
the poly-human albumin in vitro [34, 32, 35] and the mono human albumin in vivo [36, 37], more 
investigation is needed to determine whether this binding capability is involved in the viral attachment.  
SHBs, the most abundant viral glycoprotein, certainly has a role in virus secretion [24].  Its role in 
virus uptake is supported by the studies of Leenders and his colleagues [38]. Using recombinant HBs 
protein, they have performed binding studies with adult human hepatocytes, rat hepatocytes, human 
fibroblasts, human peripheral blood mononuclear cells and plasma membranes derived from these cell 
types. The results suggest that SHBs was able to bind specifically to human hepatocytes, human 
fibroblasts and human blood mononuclear cells but not the rat hepatocytes. This binding could be 
inhibited by recombinant HBs but not by the recombinant LHBs. The binding of SHBs with human 
hepatocytes was further supported by the observation from Bruin et al [39]. They have found that the 
particles only composed by SHBs can bind the human hepatocyte plasma membrane and this binding 
resulted in the internalization of the gold labeled sub viral particles [25].  
However, despite the literature about HBV surface proteins, determination of which of the proteins 
is centrally responsible for HBV attachment and entry is elusive. Recently, synthetic beads conjugated 
to viral proteins were used to quantitatively measure virus–cell attachment, at the level of single cell 
resolution, by light microscopy [25]. In addition to attachment, entry of the HBV–protein conjugated 
beads into the cells can be easily detected by scanning and transmission electron microscopy. It was 
found that the beads conjugated with the recombinant preS1 protein containing the prominent QLDPAF 
motif, but lacking the small HBsAg regions, show efficiently attach to cells. Interestingly, beads 
conjugated with particles containing the whole repertoire of the surface proteins were twice as active in 
attachment, compared to preS1 alone. Thus, it appears that it is possible HBV uptake involves multiple 
attachment sties [17].  
3.  The cell receptor for HBV attachment. 
It is also unclear as to the identity of the cellular macromolecules that are responsible for virus 
attachment. Since HBV is highly infectious, in vivo, the relative refractoriness of liver cells, grown in 
culture, has been something of a puzzle.  The Studies duck hepatitis B virus (DHBV) infection with 
primary duck hepatocytes have been particularly revealing. In 1994, then in 1995, Kuroki et al. reported Int. J. Med. Sci. 2004 1(1): 21-33  24 
that a glycoprotein in duck hepatocytes with the molecular weight 180 Kilo Dalton, called gp180, can 
be co-precipitated with DHBV [40, 41]. Moreover, the interaction of gp180 and DHBV can be blocked 
by monoclonal anti duck large protein antibodies. Subsequent cDNA cloning revealed the binding 
protein to be a carboxypeptidase H-like molecule, now classified as duck carboxypeptidase D (DCPD). 
Li and Tong have confirmed those [42, 43] and further demonstrated the carboxypeptidase D, a protease 
existing in the avian hepatocyte, exiting in the mammalian hepatocytes either. The protease function of 
carboxypeptidase D during the DHBV infection is unclear. The DHBV attachment receptor is a 
protease implies that hepadnavirus infection probably requires proteolysis. This will be discussed later.  
The study to identify the receptors for human HBV LHBs has been less successful.  Despite the 
fact that the specific preS1 domain for attachment of the LHBs to human liver cells and/or cell lines has 
been repeatedly verified, the cellular protein that is responsible for this binding has not been found yet. 
The limited availability of primary human tissue almost certainly hampers progress. Research has thus 
relied heavily upon human hepatoma cell lines [44]. Using a synthesized peptide with the sequence of 
HBV putative attachment site in preS1, Falco et al. have isolated a membrane protein called Hep-BP 
from HepG2 cells, which can specifically bind HBV preS1 peptide. Furthermore, they found that after 
the transfection of corresponding cDNA of Hep-BP into HepG2 cells, the virus binding capacity 
increased by 2 orders of magnitude compared with untransfected cells. Chinese hamster ovary cells, 
which normally do not bind to HBV, acquired susceptibility to HBV binding after transfection [45]. The 
sequence analysis suggests this protein is highly homologous with the squamous cell carcinoma 
(SCCA1), a serine protease inhibitor of ovalbumin family that has been used as a tumor marker for 
diagnosis of SCC [46]. However, the lack of the tissue specificity and low level expression in the liver 
cells reduce the possibility of it as a relevant receptor of HBV infection. It is worthy that Hep-BP is a 
serine protease inhibitor and is over-expressed in the cancer cells [47]. The over-expression of another 
serine protease inhibitor kazal type (SPIK) in the HepG2 and Huh 7 cells was also observed by us. The 
possible role of this protease inhibitor in the HBV infection will be discussed later.  
Using human hepatoma cell line or the membrane of human liver cells, the protein that bind HBV 
MHBs or SHBs has been reported by several groups.  In 1989, Potisso et al. reported that human liver 
plasma membranes contain receptors for MHBs via associated with polymerized human serum albumin 
[32]. Subsequently, Buine et al identified human liver endonexin II (EII) as a specific SHBs binding 
protein [48]. A sialoglycoprotein was also reported as a receptor for SHBs binding in the uptake of 
HBV [49, 50].  However, it is noted that no direct evidence to show that the interaction of HBV with 
those receptors could result in the real infection. Therefore, the full understand of the HBV attachment 
and it receptors perhaps could only be achieved after a susceptible cell line has been established. 
4.  The HBV fusion and proteolysis  
The attachment of HBV surface protein to the host cell is essential for HBV entry. However, 
attachment alone is not sufficient for viral infection.  The fusion of viral protein and cell membrane 
allows the release of the viral genome into cytosol. Attachment and fusion are two distinct events. 
Attachment usually is receptor mediated, and therefore, is highly cell specific. In contrast, viral fusion is 
dependent on a specific domain within the viral surface protein, known as the "fusion motif,” which is 
normally composed of a series of hydrophobic amino acids [51, 52, 53, 54] and is independent of 
specific cell receptors and thus relatively less cell specific.  Attachment possibly occurs at a low 
temperature of 4° C. However, fusion requires a temperature of at least 20° C.   
In 1993, we reported that HBV has a conservative region in the N-terminus of its S domain, which 
encloses a hydrophobic sequence with 13 amino acids [51]. This sequence has all the characteristics of 
fusion motif of other human viruses such as paramyxoviruses and retroviruses including of HIV, RSV 
and influenza virus [5]. More important, this region includes a core hydrophobic sequence: FLG-LL-
AG, which is supposed to trigger the viral–cell fusion [55, 56]. Notably, this sequence is conserved in 
all the hepadnavirus [5, 6]. The fusogenesis of this sequence was confirmed by Rodriguez-Crespo et al.  
Using the synthesized peptides containing this region of HBV and woodchuck hepatitis virus (WHV), 
they have demonstrated that these peptides can induce the fusion of bio-membranes, liposome leakage 
and haemolytic activity in vitro [57, 58]. We also have found that the peptides containing this sequence 
can trigger the syncytia of HepG2 cell from without (unpublished evidence).  It is noteworthy that pre-
digestion of HBV with a bacterial protease V8 allowed the HBV and WHV entry into the unsusceptible 
cell line such as HepG2 to initiate the infection [5, 6]. The reason that V8 protease treatment induces Int. J. Med. Sci. 2004 1(1): 21-33  25 
viral infectivity is not clear. However, V8 protease cleaves at a proteolytic sensitive region called 
“PEST region” that is just adjacent to the putative fusogenic domain of HBV suggests that the viral 
infection probably is the consequence of the exposure of HBV fusion domain (Figure 1 B) [5,6]. The 
proteolysis to make the viral fusion domain that does not locate at the N-terminus accessible for the 
infection was seen in the other virus [14, 59, 60].  
 The protease induced HBV infection can be enhanced by low pH. Our unpublished data showed 
that the binding of V8 digested HBV to the HepG2 cells was pH dependent. At a mild acid condition, 
for example, pH5.5, the binding ability of those HBV to Hep G2 cells was increased 60% than that at 
neutral condition. Considering of the possible exposure of HBV fusion domain by the digestion of V8 
protease, this result implies that the low pH might help HBV fusion. Low pH helps viral fusion was 
observed in other human virus such as Semliki forest virus and Influenza virus in the endocytosis way 
[14, 13, 11, 61]. It is not clear whether the uptake of HBV requires the endocytosis.  However, it was 
demonstrated that exposing the virus to the low pH triggers translocation of the internally sequence of 
PreS1 domain onto the viral surface [62, 63]. This supports the hypothesis that the low pH in the 
endosome may induce the conformation change of HBV surface proteins, furthermore, to release its 
nucleocapsid after viral-cell fusion.  
The results on the role of pH in the uptake of DHBV are inconsistent [64, 65]. Using 
lysosometropic agents, for example, ammonium chloride and chloroquine, which can raise the pH in the 
endosome, Offensperger et al. found that the uptake of DHBV has been blocked [64]. In contrast, Rigg 
et al. reported that the treatment of ammonium chloride did not affect the uptake of DHBV [65]. In spite 
both groups used the duck primary liver cell as an experimental infection system, however, the 
condition of the cell growth seems somehow different. Therefore, the contradictory observation might 
be the result of the different approaches used. Recently, Breiner and Schaller have demonstrated that the 
uptake of DHBV by primary duck hepatocyte (PDH) requires endocytosis [66]. The deficient mutant 
preventing the transport of DHBV to endosome has abolished the infection. However, the endocysis is a 
feature usually associated with low pH-triggered fusion mechanism. Altogether, while a strict low pH 
dependency may not apply to DHBV to the same extent as for certain other viruses, low pH may still 
significantly facilitate entry of the virus [17].  
5.  Internalization of HBV following attachment 
Most data about hepadnavirus internalization and transport to the nucleus was generated from the 
studies of the uptake of DHBV by duck primary hepatocytes (PDH). However, the entry route for 
DHBV is still unclear. As we have mentioned before, there are two entryways that the viruses use for 
their entry. One is via direct fusion with the host cell membrane like HIV [67] and the other is via 
endocytic pathway like Semliki forest virus and Influenza virus [13, 14]. Recent data suggests that 
DHBV may use the endocytosis way for its entry [66]. This hypothesis was supported by the 
observation of the conformation change of the large surface protein of DHBV at low pH condition [62]. 
However, the more detail investigation was from the kinetic study of the uptake of DHBV by duck 
primary hepatocyte. In 1999, Qiao and his colleagues have performed a kinetic study of DHBV uptake.  
They observed that DHBV DNA appeared in the cytosol of PDH as early as one hour after post-
incubation of virus with cells at 37 °C [68]. Nevertheless, DHBV DNA only can be detected in the 
nuclear fractions after at least 4 hours post-incubation. This suggests that the internalization happens 
immediately after the viral attachment. However, the intranuclear translocation of DHBV requires more 
time. The cccDNA and single-stranded DNA were not detected until 48 hours post inoculation (p.i.) 
[68]. Comparing with the in vivo infection, cccDNA can be detected in hepatocytes as fast as 6 hours 
after inoculation of ducks with the same DHBV strain [68], there was 40 hours delay during DHBV 
localization to the nucleus and formation of cccDNA in vitro system [68].  The reason for this delay is 
unknown.  
Until now, there is limited data about HBV internalization and transport to the nucleus. However, 
the study of HBV infection to human primary hepatocytes shows that the cccDNA of HBV appeared in 
the nucleus after two days of the post inoculation, this is agreement with the observation from DHBV 
[69]. The result from the kinetic study on the internalization and transportation of HBV by the HepG2 
cells is somehow different with the result from the primary hepatocytes.  HepG2 is capable of 
supporting viral replication and producing progeny viruses. However, this cell-line is generally 
refractory with the infection of serum derived HBV [5, 15] in spite the post attachment internalization Int. J. Med. Sci. 2004 1(1): 21-33  26 
of HBV in HepG2 cells was observed by several groups [15, 49]. According to the observation from the 
Qiao’s group, the internalization of HBV by HepG2 cells happened immediately after the viral 
attachment, and reached its peak within the cytosol two hours after post incubation at 37 °C. This was 
similar to the process in DHBV infection. However, the nuclear transport of HBV DNA was not 
completed even 16 hours following viral absorption [15]. The disability of transport of HBV DNA to 
nucleus implies that the release of HBV nucleocapsid in the HepG2 cells was blocked by some 
unknown facts after the viral internalization. Perhaps deficiencies in viral transport to the nucleus are 
part of the reason that HepG2 cells are refractory to HBV infection. Considering the proteolysis 
enhances in vitro HBV infection of HepG2 cells, it is possible that the block of HBV nucleocapsid 
transport is a consequence of the lack of necessary protease digestion.  
It is still unclear whether the internalization of HBV requires a permeable domain with the 
sequence of PLSSIFSRIGDP at middle of preS2, which was reported by Oess and his colleagues 
recently (Figure 1B) [70].  It was shown that this domain mediated the internalization of a fused protein 
into Hela cells [70]. CD spectroscopy revealed the sequence of PLSSIFSRIGDP consists of a 
hydrophobic region that contains internal, charged, hydrophilic residues and had the ability to fold into 
an amphipathic alpha-helix, which has been identified conferring the unexpected property of cell 
permeability in other viruses [71]. Examples include the antennapedia homeo domain [53], HIV-tat 
transcription factor [72], Herpes simple virus vp22 [73] and lactoferrin [74]. It is interesting that this 
permeable domain is just adjacent with PEST-fusion region of HBV (Figure 1 B).  The role of this 
permeable domain in HBV internalization needs further investigation.   
6.  Over-expression of Serine protease inhibitor Kazal in the HBV insusceptible 
hepatoma cell lines 
If the refractoriness of HepG2 cells to HBV infection is related to the lack of requisite proteolysis, 
the conclusion might be that the HepG2 cells perhaps do not have these specific proteases or they do 
have these proteases, however, they are inactivated by an unknown agent. To find clues as to the nature 
of HepG2 refractoriness to HBV infection, we have compared the gene expression profile of HBV 
susceptible primary human liver and HepG2 cells, with an eye on expression of RNA specifying 
proteases and their inhibitors, using a gene array system. The results show that there were no detected 
differences in the protease profile. However, the expression of a serine protease inhibitor Kazal (SPIK) 
was more than a thousand fold higher in HepG2 cells than in human liver cells (unpublished data). At 
the same time, the expressions of the most other genes were found to be approximately equal amongst 
HepG2 cells and human liver cells (unpublished gene array data). This suggests a role for SPIK in the 
altered phenotype of HepG2 cells with respect to liver cells and possibly a role in their susceptibility 
differences to HBV infection. These finding that SIPK was over expressed in HepG2 cells, relative to 
primary liver tissue, was confirmed by reverse-transcription PCR (RT-PCR) and Northern blot analysis.  
 As shown in figure 2, two specific primer sets, PI1/ PI2 and PI3/PI4, were used to amplify SPIK 
mRNA by RT-PCR. PI1/PI2 directly amplifies the SPIK gene from the 11
th bp to233
th bp and PI3/PI4 
directly amplifies the entire SPIK gene (Figure 2A). The RT-PCR band generated from primers PI3/PI4 
was at the predicted size and slightly larger than that one generated from primers PI1/PI2 (324 base 
pairs versus 224 base pairs (Figure 2B). This suggests that the reactions of RT-PCR were specific. In 
addition, these bands were not generated from SPIK DNA (gene sequences), because the control that 
lacked the enzyme reverse transcriptase in the reaction mixture did not show any band (Figure 2B, lane 
9). Compared to human liver cells, the expression of SPIK gene in the HepG2 cells was overwhelming. 
Using either of the primer sets, SPIK specific bands can be easily detected in the HepG2 cells, but 
hardly in the human liver cells (Figure 2B).  This difference was not a result of the variation of loading, 
because the expression of the thimet oligopeptidase gene in the same condition did not show any 
difference (Figure 2C).  
The over-expression of the SPIK gene in HepG2 cells has also been confirmed by Northern blot 
analysis. Ten micrograms RNA from HepG2 cells and human liver cells were resolved on a 1% non-
denatured agarose gel, subsequently transferred to a nylon membrane, and then hybridized with a 
32P 
labeled SPIK specific probe derived from the SPIK gene by PCR. In agreement with the results from 
RT-PCR, figure 3 shows that the SPIK mRNA can only be detected in the HepG2 cells. The signal in 
the human liver cells was invisible (Figure 3, Northern blot, lane 2 & lane 3). The undetectable signal 
from human liver cells was not as a result of the unequal loading. The equality of RNAs were applied Int. J. Med. Sci. 2004 1(1): 21-33  27 
on to the gel as evidenced by the equivalent ethidium bromide (EB) staining of ribosomal RNA in both 
samples (Figure 3, EB stain lane 2 and lane 3. See 18S and 26S ribosome RNA). Similar increase of the 
SPIK expression was observed in yet another hepatoma cell line Huh7, which is also refractory to HBV 
infection similarly to HepG2 (Figure 3. Northern blot, lane 1). Taken together, these results demonstrate 
that SPIK gene is over-expressed in cells that are not susceptible to HBV infection, such as HepG2 and 
Huh7 cells. In contrast, the expression of SPIK maintains at undetectable level in the HBV infectible 
cells such as the normal human liver cells.  Although, this needs to be further investigated, it is also 
worth noting that if over expression of SIPK is common to hepatoblastoma and other cancer cells, it 
could be a useful biomarker for early detection of cancer (Lu, in progress). 
7.  Systems used for the study of HBV infection. 
As we have mentioned before, the major limitation to study HBV entry is the lack of an in vitro 
infection system, which can support the entire life cycle of HBV. Human primary hepatocyte cultures 
derived from liver explants have been shown to be susceptible to HBV infection, but only for a limited 
amount of time following explantation [75, 76]. Besides of the human primary hepatocytes, there are 
several systems derived from Hepatoma cells so far were used for the study of HBV infection in vitro 
[68, 77, 78, 16, 79]. Unfortunately, no one of them is perfect. This includes the manipulation of the 
cultured HepG2 cells with dimethyl sulfoxide (DMSO) or polyethyleneglycol (PEG), which has been 
reported to enhance HBV infection in vitro [68, 77]. Currently, a cell line susceptible to HBV infection 
was reported by Grippon et al. [16]. However, the high dose of DMSO and 2-4% PEG were used in this 
system to maintain susceptibility greatly limits their application for study the natural infection of HBV. 
Therefore, although cultured cells can be shown to support HBV replication, there is yet no readily 
reproducible tissue culture system for HBV infectivity.  
The finding of over expression of SPIK in the HepG2 cells and Huh 7 cells may suggest a strategy 
to establish a stable cell line that is susceptible for HBV infection by silencing those over expressed 
proteases inhibitor.  Admittedly, the cause and effect relationship between over expression of SIPK and 
refractoriness to HBV is a long shot.  Never the less, it could be tested by straightforward techniques 
that were in use in the lab for other purposes. Antisense oligonucleotides have been used previously to 
silence specific genes [80]. In one experiment, HepG2 cells were pre-treated with 10 nM anti-sense or 
sense oligo corresponding to the translation initiation region of SPIK gene. After 2 days, cells were then 
infected with HBsAg positive patient’s serum (10
7 viruses /ml). The progeny HBV both in the medium 
and in the cytosol were examined. By 3 days after the inoculation, the amount of HBsAg in the culture 
medium fell below the level of detection.  However, the level of HBsAg in the culture medium from 
HepG2 cells pre-treated with anti-sense of SPIK significantly increased on the 4th day and 5th day post 
infection (p.i.), then decreased but maintained in a detectable level until harvest (7 days post infection, 
figure 4). On the other hand, HBsAg in the culture medium from cells that were treated with sense oligo 
of SPIK were at background levels during entire period (figure 4). A similar result was found in the 
untreated HepG2 cells (data not shown).  
HepG2 cells were susceptible to HBV infection after treatment with SPIK specific anti-sense oligo 
was confirmed by the results from Southern blot. At 8th day post infection, the replicative form of HBV 
in cytoplasm was detected feebly in infected cells that were pre-treated with anti-sense of SPIK (Figure 
5. lane 1).  However, no HBV DNA was found in cells treated with SPIK sense oligo or when untreated 
(Figure 5. lane 2, 3). The examining cccDNA in the nuclear fraction of infected cells was unsuccessful. 
It is likely that the levels were far below the detection limit. 
In spite the signals from infected cells were not very intense (this may be due to the less efficiently 
transport of anti-sense oligo to the cells), but were reproducibly present. However, the fact that HepG2 
cells appear to be successfully infected by HBV following marginal down regulation of SPIK gene 
expression supports our hypothesis that the suppression of the over-expression of SPIK gene might 
reinstate the susceptibility of HepG2 cell to HBV infection by the restoration of the activity of 
indispensable protease. Currently, a new technology called RNA interference (RNAi) or short 
interfering RNA (siRNA) was developed to silence target gene expression [81, 82, 83]. Using this 
method a stable cell line, in which the SPIK gene is silenced, could be established by using of the 
specific siRNA, and then be selected by co-expressing a selectable gene such as the neo gene through 
screening with G418 [84]. After screening with G418, all surviving cells would be expected to generate 
the specific siRNA silencing the targeted SPIK expression. The early results are, never the less, Int. J. Med. Sci. 2004 1(1): 21-33  28 
provocative, and beg further investigation.  An effort, for example, to establish a susceptible cell line to 
HBV infection by silencing SIPK is now under way.  
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Figures 
Figure 1. The structure of Hepatitis B virus surface proteins and its interesting regions for infection. A. 
The structure of HBsAg. B. The location of the interesting regions for HBV infection. 
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Figure 2. RT-PCR detects SPIK RNA. 1µg RNA from HepG2 cells and human liver cells were 
reversely transcripted and amplified by PCR using specific primer for SPIK. PCR bands were resolved 
in 1 % agarose gel and stain with ethidium Bromide. A: The names and location of primers. B: RT-PCR 
results. Lanes 1 to 4 were amplified with primers PI1/PI2; 5 to 8 were amplified with primers PI3/PI4. 
The samples from human liver cells were loaded in the column 1,2,5,6, (duplicated). The samples from 
HepG2 were loaded in the lane 3,4,7,8. Lane 9 was negative control without RTase. The specific SPIK 
bands are indicated by molecular weight. The lower bands in B are dimmer of primers. C: RT-PCR 
detection of TH gene of the human liver cells and HepG2 cells. 
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Figure 3. Northern blot detects SPIK. 10µg RNA from Huh7 (1), HepG2 (2) and human liver cells 
purchased from CloneTech (3) were resolved in the 1% non-denatured agarose gel, then, transferred to 
nylon membrane. The membrane was hybridized with 32p labeled SPIK specific probe. The image of 
ethidium bromide (EB) staining was taken from gel before transference. The image of northern blot was 
determined by phosphateImager. 
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Figure 4. Secreted HBsAg in the HepG2 cells pre-treated with anti-sense of SPIK. HepG2 cells were 
pre-treated with 10nM/ml anti-sense or sense oligo of SPIK two days. Then, cells were infected with 
HBsAg positive patients’ serum. The secreted HBsAg in the culture medium was detected by Auszyme 
kit (Abbott Lab. Abbott Park, IL). 
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Figure 5. Southern blot detection of HBV DNA in the infected HepG2 cells. 10
6 HepG2 cells were pre-
treated with anti-sense or sense oligo of SPIK or left untreated, then infected by patients’ serum. Cells 
were harvested at 8
th day p.i. After removal of nuclei, HBV DNA in cytoplasma was isolated, resolved 
in 1% agarose gel and detected by southern blot with HBV specific probe. 
 
 
 